Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma

被引:25
|
作者
Kim, Bo Hyun [1 ,2 ]
Kim, Seong-Jang [2 ,3 ]
Kim, Heeyoung [3 ]
Jeon, Yun Kyung [1 ]
Kim, Sang Soo [1 ]
Kim, In Joo [2 ,3 ]
Kim, Yong Ki [4 ]
机构
[1] Pusan Natl Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Pusan 602739, South Korea
[2] Pusan Natl Univ Hosp, Biomed Res Inst, Pusan 602739, South Korea
[3] Pusan Natl Univ Hosp, Dept Nucl Med, Pusan 602739, South Korea
[4] Kim Yong Ki Internal Med Clin, Pusan, South Korea
关键词
fluorine-18; fluorodeoxyglucose; metabolic tumor volume; PET; thyroid neoplasms; POSITRON-EMISSION-TOMOGRAPHY; CLINICAL-SIGNIFICANCE; CANCER; F-18-FLUORODEOXYGLUCOSE; CARCINOMA; PREVALENCE; MALIGNANCY; RISK; HEAD;
D O I
10.1097/MNM.0b013e328362d2d7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background The objective of the study was to investigate whether metabolic tumor volume (MTV) measured by fluorine-18 fluorodeoxyglucose (F-18-FDG) PET/computed tomography (PET/CT) after stratification of serum thyroid stimulating hormone (TSH) levels could predict malignancy in patients with thyroid F-18-FDG incidentaloma.Materials and methods A total 262 patients with focal thyroid F-18-FDG incidentaloma undergoing cancer evaluation for nonthyroid cancer or a health checkup were enrolled in this study. We retrospectively evaluated the relationship of the maximum standardized uptake value (SUVmax) and MTV in the prediction of malignant thyroid F-18-FDG incidentaloma.Results The prevalence of malignancy was 20.9% (37/177). Malignant thyroid incidentaloma had a statistically significant higher value of SUVmax (malignant: median 4.6, range 1.9-34.9; benign: median 4.1, range 0-28; P=0.030). The value of MTV4 in malignant thyroid incidentaloma was significantly higher than that of benign thyroid incidentaloma (malignant: median 0.16, range 0.02-1.19; benign: median 0.10, range 0-0.65; P=0.032). However, the values of MTV3.5, MTV3, and MTV2.5 did not differ significantly between the groups. After stratification of serum TSH levels (an SUVmax>5 was used as the cutoff point) the sensitivity and specificity for prediction of malignancy were found to be 61.1% [95% confidence interval (CI): 35.7-82.7%] and 68.7% (95% CI: 56.2-79.4%), respectively. The area under the curve (AUC) was 0.655 (95% CI: 0.545-0.755; P=0.0239). When MTV4 greater than 0.07 cm(3) was used as the cutoff point, the sensitivity and specificity for prediction of malignancy were 81.2% (95% CI: 54.4-96.0%) and 50.0% (95% CI: 37.0-63.0%), respectively. The AUC was 0.650 (95% CI: 0.534-0.755; P=0.0451). On comparison receiver operating characteristic curve analysis, no significant difference was found between SUVmax and MTV4 in the prediction of thyroid carcinoma (P=0.4346). However, a combination of SUVmax and MTV4 resulted in an AUC of 0.669 (95% CI: 0.554-0.772; P=0.0183).Conclusion The SUVmax and MTV4 measured by F-18-FDG PET/CT after stratification of serum TSH levels could predict thyroid cancer in patients with thyroid F-18-FDG incidentaloma. A combination of SUVmax and MTV4 may be more useful for the differentiation of malignant from benign thyroid incidentaloma.
引用
收藏
页码:868 / 876
页数:9
相关论文
共 50 条
  • [11] SUVmax of 18F-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume
    Tae Heon Kim
    Yong Bae Ji
    Chang Myeon Song
    Ji Young Kim
    Yun Young Choi
    Jeong Seon Park
    Kyung Tae
    World Journal of Surgical Oncology, 13
  • [12] MANAGEMENT PRINCIPLES OF INCIDENTAL THYROID 18F-FDG UPTAKE IDENTIFIED ON 18F-FDG PET/CT IMAGING
    Akbas, A.
    Dagmura, H.
    Gul, S.
    Dasiran, F.
    Daldal, E.
    Okan, I
    ACTA ENDOCRINOLOGICA-BUCHAREST, 2022, 18 (02) : 253 - 257
  • [13] Added predictive value of 18F-FDG PET/CT for pediatric rhabdomyosarcoma
    El-Kholy, Esraa
    EL Nadi, Enas
    Hafez, Hanafy
    Ahmed, Soha
    Younes, Alaa
    EL-Kenanii, Naglaa
    Khalid, Elham
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (09) : 898 - 904
  • [14] The Added Value of 18F-FDG PET/CT for Evaluation of Patients with Esthesioneuroblastoma
    Broski, Stephen M.
    Hunt, Christopher H.
    Johnson, Geoffrey B.
    Subramaniam, Ratham M.
    Peller, Patrick J.
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (08) : 1200 - 1206
  • [15] Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma
    Fonti, Rosa
    Larobina, Michele
    Del Vecchio, Silvana
    De Luca, Serena
    Fabbricini, Rossella
    Catalano, Lucio
    Pane, Fabrizio
    Salvatore, Marco
    Pace, Leonardo
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (12) : 1829 - 1835
  • [16] Prognostic value of metabolic tumor volume and total lesion glycolysis assessed by 18F-FDG PET/CT in endometrial cancer
    Erdogan, Mehmet
    Erdemoglu, Evrim
    Evrimler, Sehnaz
    Hanedan, Candost
    Sengul, Sevim S.
    NUCLEAR MEDICINE COMMUNICATIONS, 2019, 40 (11) : 1099 - 1104
  • [17] 18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer
    Krause, Bernd J.
    Herrmann, Ken
    Wieder, Hinrich
    zum Bueschenfelde, Christian Meyer
    JOURNAL OF NUCLEAR MEDICINE, 2009, 50 : 89S - 96S
  • [18] The Performance of 18F-FDG PET and 18F-FDG PET/CT in Detection of Carcinoma of Unknown Primary
    Dong, M.
    Zhao, K.
    Zhao, J.
    Guan, Y.
    Liu, Z.
    Ruan, L.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2008, 35 : S275 - S275
  • [19] 18F-FDG PET/MRI versus 18F-FDG PET/CT for the diagnosis of pituitary adenoma
    Wang, Hao
    Zhao, Xiaobin
    Zang, Jie
    Zhu, Zhaohui
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [20] Usefulness of 18F-FDG PET/CT in thyroid carcinoma
    Muros de Fuentes, M. A.
    Mitjavila Casanovas, M.
    Estorch Cabrera, M.
    Lecumberri Santamaria, B.
    Navarro Gonzalez, E.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2016, 35 (03): : 186 - 192